본문 바로가기
KERD
논문KCI 등재

Targeting Arginine-Dependent Cancers with Arginine-Degrading Enzymes: Opportunities and Challenges

Melissa M. Phillips|Michael T. Sheaff|Peter W. Szlosarek
대한암학회 (Korean Cancer Association)|2013.12|Cancer Research and Treatment|제45권 제4호|pp. 251-262|DOI http://dx.doi.org/10.4143/crt.2013.45.4.251

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

NeoplasmsArginineDrug combinationsArginaseArgininosuccinate synthetaseArgininosuccinate lyaseADI-PEG20
주제분류의학일반

초록

Arginine deprivation is a novel antimetabolite strategy for the treatment of argininedependent cancers that exploits differential expression and regulation of key urea cycle enzymes. Several studies have focused on inactivation of argininosuccinate synthetase 1 (ASS1) in a range of malignancies, including melanoma, hepatocellular carcinoma (HCC), mesothelial and urological cancers, sarcomas, and lymphomas. Epigenetic silencing has been identified as a key mechanism for loss of the tumor suppressor role of ASS1 leading to tumoral dependence on exogenous arginine. More recently, dysregulation of argininosuccinate lyase has been documented in a subset of arginine auxotrophic glioblastoma multiforme, HCC and in fumarate hydratasemutant renal cancers. Clinical trials of several arginine depletors are ongoing, including pegylated arginine deiminase (ADI-PEG20, Polaris Group) and bioengineered forms of human arginase. ADI-PEG20 is furthest along the path of clinical development from combinatorial phase 1 to phase 3 trials and is described in more detail. The challenge will be to identify tumors sensitive to drugs such as ADI-PEG20 and integrate these agents into multimodality drug regimens using imaging and tissue/fluid-based biomarkers as predictors of response. Lastly, resistance pathways to arginine deprivation require further study to optimize arginine-targeted therapies in the oncology clinic.

Abstract

Arginine deprivation is a novel antimetabolite strategy for the treatment of argininedependent cancers that exploits differential expression and regulation of key urea cycle enzymes. Several studies have focused on inactivation of argininosuccinate synthetase 1 (ASS1) in a range of malignancies, including melanoma, hepatocellular carcinoma (HCC), mesothelial and urological cancers, sarcomas, and lymphomas. Epigenetic silencing has been identified as a key mechanism for loss of the tumor suppressor role of ASS1 leading to tumoral dependence on exogenous arginine. More recently, dysregulation of argininosuccinate lyase has been documented in a subset of arginine auxotrophic glioblastoma multiforme, HCC and in fumarate hydratasemutant renal cancers. Clinical trials of several arginine depletors are ongoing, including pegylated arginine deiminase (ADI-PEG20, Polaris Group) and bioengineered forms of human arginase. ADI-PEG20 is furthest along the path of clinical development from combinatorial phase 1 to phase 3 trials and is described in more detail. The challenge will be to identify tumors sensitive to drugs such as ADI-PEG20 and integrate these agents into multimodality drug regimens using imaging and tissue/fluid-based biomarkers as predictors of response. Lastly, resistance pathways to arginine deprivation require further study to optimize arginine-targeted therapies in the oncology clinic.

참고문헌 (106)

  1. Hanahan D, "Hallmarks of cancer: the next generation", Cell, 144, pp.646~674 (2011)
  2. Schiffman JD, "No child left behind in SDHB testing for paragangliomas and pheochromocytomas", J Clin Oncol, 29, pp.4070~4072 (2011)
  3. Vander Heiden MG, "Targeting cancer metabolism: a therapeutic window opens", Nat Rev Drug Discov, 10, pp.671~684 (2011)
  4. Broome JD, "Evidence that the L-asparaginase activity of Guinea pig serum is responsible for its antilymphoma effects. Nature", Nature, 191, pp.1114~1115 (1961)
  5. Richards NG, "Asparagine synthetase chemotherapy", Annu Rev Biochem, 75, pp.629~654 (2006)
  6. Jaffe N, "Favorable remission induction rate with twice weekly doses of L-asparaginase", Cancer Res, 33, pp.1~4 (1973)
  7. Douer D., "Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia", Best Pract Res Clin Haematol, 21, pp.647~658 (2008)
  8. Truelove E, "The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia", Leukemia, 27, pp.553~559 (2013)
  9. Offman MN, "Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity", Blood, 117, pp.1614~1621 (2011)
  10. Wheatley DN, "Controlling cancer by restricting arginine availability: arginine-catabolizing enzymes as anticancer agents", Anticancer Drugs, 15, pp.825~833 (2004)
  11. Feun L, "Pegylated arginine deiminase: a novel anticancer enzyme agent", Expert Opin Investig Drugs, 15, pp.815~822 (2006)
  12. Husson A, "Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle", Eur J Biochem, 270, pp.1887~1899 (2003)
  13. Dillon BJ, "Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation", Cancer, 100, pp.826~833 (2004)
  14. Szlosarek PW, "Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer", Int J Cancer, 121, pp.6~11 (2007)
  15. Delage B, "Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer", Int J Cancer, 126, pp.2762~2772 (2010)
  16. Delage B, "Promoter methylation of argininosuccinate synthetase- 1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis", Cell Death Dis, 3, pp.e342~ (2012)
  17. Tsai WB, "Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc", HIF-1alpha, Mol Cancer Ther, pp.2009, 8[DOI]
  18. Kobayashi E, "Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma", Mol Cancer Ther, 9, pp.535~544 (2010)
  19. Huang HY, "ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance", Clin Cancer Res, 19, pp.2861~2872 (2013)
  20. Allen M, "Prognostic and therapeutic impact of argininosuccinate synthetase-1 control in bladder cancer as monitored longitudinally by PET imaging", Cancer Res, 27 (2013)[DOI]
  21. Osunkoya BO, "Effect of arginine deficiency on synthesis of DNA and immunoglobulin receptor of Burkitt lymphoma cells", Nature, 227, pp.398~399 (1970)
  22. Yamauchi K, "Glutamine and arginine affect Caco-2 cell proliferation by promotion of nucleotide synthesis", Nutrition, 18, pp.329~333 (2002)
  23. Long Y, "Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction", Mol Cancer Ther, 12, pp.2581~2590 (2013)
  24. Braas D, "Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatment", Cancer Discov, 2, pp.1109~1117 (2012)
  25. Van Tine BA, "Using pegylated arginine deiminase (ADI-PEG20) for the treatment of sarcomas that lack argininosuccinate synthesase 1 expression", J Clin Oncol, 31(S), pp.10526~ (2013)
  26. Lan J, "Deficiency in expression and epigenetic DNA methylation of ASS1 gene in nasopharyngeal carcinoma: negative prognostic impact and therapeutic relevance", Tumour Biol, 30 (2013)[DOI]
  27. Possemato R, "Functional genomics reveal that the serine synthesis pathway is essential in breast cancer", Nature, 476, pp.346~350 (2011)
  28. Erez A, "Requirement of argininosuccinate lyase for systemic nitric oxide production", Nat Med, 17, pp.1619~1626 (2011)
  29. Huang HL, "Attenuation of argininosuccinate lyase inhibits cancer growth via cyclin A2 and nitric oxide", Mol Cancer Ther, 12, pp.2505~2516 (2013)
  30. Syed N, "Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma", Cell Death Dis, 4, pp.e458~ (2013)
  31. Zheng L, "Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells", Cancer Metab, 1, pp.12~ (2013)
  32. Adam J, "A role for cytosolic fumarate hydratase in urea cycle metabolism and renal neoplasia", Cell Rep, 3, pp.1440~1448 (2013)
  33. Feun LG, "Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine- depleting therapy with pegylated arginine deiminase", Br J Cancer, 106, pp.1481~1485 (2012)
  34. Kelly MP, "Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase", Br J Cancer, 106, pp.324~332 (2012)
  35. Szlosarek PW, "In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion", Clin Cancer Res, 12, pp.7126~7131 (2006)
  36. Gilroy E, "The influence of arginine upon the growth rate of a transplantable tumour in the mouse", Biochem J, 24, pp.589~595 (1930)
  37. Yeatman TJ, "Depletion of dietary arginine inhibits growth of metastatic tumor", Arch Surg, 126, pp.1376~1381 (1991)
  38. Bach SJ, "Some aspects of the role of arginine and arginase in mouse carcinoma 63", Enzymologia, 12, pp.198~205 (1947)
  39. Storr JM, "The effects of arginine deficiency on lymphoma cells", Br J Cancer, 30, pp.50~59 (1974)
  40. Scott L, "Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells", Br J Cancer, 83, pp.800~810 (2000)
  41. Takaku H, "In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini", Int J Cancer, 51, pp.244~249 (1992)
  42. Ensor CM, "Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo", Cancer Res, 62, pp.5443~5450 (2002)
  43. Bowles TL, "Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase", Int J Cancer, 123, pp.1950~1955 (2008)
  44. Hernandez CP, "Pegylated arginase I: a potential therapeutic approach in T-ALL", Blood, 115, pp.5214~5221 (2010)
  45. Kim RH, "Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis", Cancer Res, 69, pp.700~708 (2009)
  46. Wu FL, "RNA interference of argininosuccinate synthetase restores sensitivity to recombinant arginine deiminase (rADI) in resistant cancer cells", J Biomed Sci, 18(25) (2011)
  47. Stelter L, "Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma", J Nucl Med, 53, pp.281~286 (2012)
  48. Gong H, "Arginine deiminase inhibits cell proliferation by arresting cell cycle and inducing apoptosis", Biochem Biophys Res Commun, 261, pp.10~14 (1999)
  49. Gong H, "Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis", Leukemia, 14, pp.826~829 (2000)
  50. Morrow K, "Anti-leukemic mechanisms of pegylated arginase I in acute lymphoblastic T-cell leukemia", Leukemia, 27, pp.569~577 (2013)
  51. Laplante M, "mTOR signaling in growth control and disease", Cell, 149, pp.274~293 (2012)
  52. Rhoads JM, "Arginine stimulates intestinal cell migration through a focal adhesion kinase dependent mechanism", Gut, 53, pp.514~522 (2004)
  53. Rhoads JM, "Arginine stimulates cdx2-transformed intestinal epithelial cell migration via a mechanism requiring both nitric oxide and phosphorylation of p70 S6 kinase", J Nutr, 138, pp.1652~1657 (2008)
  54. Fu YM, "Specific amino acid restriction inhibits attachment and spreading of human melanoma via modulation of the integrin", focal adhesion kinase pathway and actin cytoskeleton remodeling, 2004, pp.21, 587~598
  55. Wilm M, "Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry", Nature, 379, pp.466~469 (1996)
  56. Park IS, "Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth", Br J Cancer, 89, pp.907~914 (2003)
  57. Stelter L, "Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma", Mol Imaging, 12, pp.67~73 (2013)
  58. Gong H, "Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: potentiation by irradiation", Int J Cancer, 106, pp.723~728 (2003)
  59. Touz MC, "Arginine deiminase has multiple regulatory roles in the biology of Giardia lamblia", J Cell Sci, 121(Pt 17), pp.2930~2938 (2008)
  60. Morris SM Jr, "Recent advances in arginine metabolism: roles and regulation of the arginases", Br J Pharmacol, 157, pp.922~930 (2009)
  61. Wu G, "Arginine metabolism: nitric oxide and beyond", Biochem J, 336, pp.1~17 (1998)
  62. Leong HX, "Short-term arginine deprivation results in large-scale modulation of hepatic gene expression in both normal and tumor cells: microarray bioinformatic analysis", Nutr Metab, 3(37) (2006)
  63. Brasse-Lagnel CG, "Amino acid regulation of mammalian gene expression in the intestine", Biochimie, 92, pp.729~735 (2010)
  64. Shen LJ, "Resistance to the anti-proliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase", Cancer Lett, 191, pp.165~170 (2003)
  65. Kim RH, "autophagy and apoptosis: metabolic stress as a therapeutic option for prostate cancer", Autophagy, 5, pp.567~568 (2009)
  66. "Involvement of autophagy in recombinant human arginase-induced cell apoptosis and growth inhibition of malignant melanoma cells. Appl Microbiol Biotechnol"[URL]
  67. Commisso C, "Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells", Nature, 497, pp.633~637 (2013)
  68. Iwamoto S, "Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase", J Clin Invest, 117, pp.1049~1057 (2007)
  69. Ehsanipour EA, "Avramis VI, et al. Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine", Cancer Res, 73, pp.2998~3006 (2013)
  70. Ellyard JI, "Alternatively activated macrophage possess antitumor cytotoxicity that is induced by IL-4 and mediated by arginase-1", J Immunother, 33, pp.443~452 (2010)
  71. Zea AH, "Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion", Cancer Res, 65, pp.3044~3048 (2005)
  72. Kwong-Lam F, "Vincristine could partly suppress stromal support to T-ALL blasts during pegylated arginase I treatment", Exp Hematol Oncol, 2(11) (2013)
  73. Phillips M, "Arginine metabolism and tumour associated macrophages, In Tumour-associated macrophages", pp.77~90 (2012), Springer
  74. Cheng PN, "Pegylated recombinant human arginase (rhArgpeg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion", Cancer Res, 67, pp.309~317 (2007)
  75. Tsai WB, "Activation of Ras", PI3K, Cancer Res, pp.2012, 72[DOI]
  76. You M, "TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation", Mol Cell Biochem, 374, pp.181~190 (2013)
  77. Vynnytska BO, "Canavanine augments proapoptotic effects of arginine deprivation in cultured human cancer cells", Anticancer Drugs, 22, pp.148~157 (2011)
  78. Vynnytska-Myronovska B, "Single amino acid arginine starvation efficiently sensitizes cancer cells to canavanine treatment and irradiation", Int J Cancer, 130, pp.2164~2175 (2012)
  79. Deorukhkar A, "Arginine deiminase: a novel radiosensitizer in pancreatic cancer in vitro and in vivo", 2014 ASCO Gastrointestinal Cancers Symposium, pp.221~ (2014), Abstr
  80. Daylami R, "Arginine deprivation by PEG-ADI induces autophagic cell death and enhances the tumor suppression effect of gemcitabine in pancreatic cancer", 2010 AACR 101st Annual Meeting, pp.484~ (2010), Abstr
  81. Li Y, "Thymidylate synthase was associated with patient prognosis and the response to adjuvant therapy in bladder cancer", BJU Int, 103, pp.547~552 (2009)
  82. Takezawa K, "Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer", Br J Cancer, 104, pp.1594~1601 (2011)
  83. Righi L, "Thymidylate synthase but not excision repair crosscomplementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy", J Clin Oncol, 28, pp.1534~1539 (2010)
  84. Sigmond J, "Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression", Biochem Pharmacol, 66, pp.431~438 (2003)
  85. Edler D, "Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival", Clin Cancer Res, 6, pp.488~492 (2000)
  86. Helleman J, "Molecular profiling of platinum resistant ovarian cancer", Int J Cancer, 118, pp.1963~1971 (2006)
  87. Melaiu O, "A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma", Mutat Res, 750, pp.132~140 (2012)
  88. Nicholson LJ, "Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer", Int J Cancer, 125, pp.1454~1463 (2009)
  89. Chow AK, "Anti-tumor efficacy of a recombinant human arginase in human hepatocellular carcinoma", Curr Cancer Drug Targets, 12, pp.1233~1243 (2012)
  90. Savaraj N, "Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma", Curr Mol Med, 10, pp.405~412 (2010)
  91. Sikora AG, "Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy", Clin Cancer Res, 16, pp.1834~1844 (2010)
  92. Grimm EA, "Molecular pathways: inflammation-associated nitric-oxide production as a cancersupporting redox mechanism and a potential therapeutic target", Clin Cancer Res, 19, pp.5557~5563 (2013)
  93. Stone E, "Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy", J Control Release, 158, pp.171~179 (2012)
  94. Agrawal V, "Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells", Anticancer Drugs, 23, pp.51~64 (2012)
  95. Mauldin JP, "Recombinant human arginase toxicity in mice is reduced by citrulline supplementation", Transl Oncol, 5, pp.26~31 (2012)
  96. Glazer ES, "Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts", Transl Oncol, 4, pp.138~146 (2011)
  97. -induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells, "Leuk Res", 2013, 1565~1571
  98. Izzo F, "Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I", II studies, 2004, pp.22, 1815~1822
  99. Ascierto PA, "Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies", J Clin Oncol, 23, pp.7660~7668 (2005)
  100. Glazer ES, "Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma", J Clin Oncol, 28, pp.2220~2226 (2010)
  101. Ott PA, "Phase I", II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma, 2013, pp.31, 425~434
  102. Yang TS, "A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients", Br J Cancer, 103, pp.954~960 (2010)
  103. Szlosarek PW, "A randomised phase II trial of pegylated arginine deiminase (ADI-PEG20) in patients with malignant pleural mesothelioma (MPM)", 2013 World Conference on Lung Cancer, pp.27~30 (2013)
  104. Yau T, "A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma", Invest New Drugs, 31, pp.99~107 (2013)
  105. Szlosarek PW, "Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase", J Clin Oncol, 31, pp.e111~113 (2013)
  106. Stelter L, "Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET", Mol Imaging Biol, 15, pp.768~775 (2013)

관련 논문AI추천

Arginine Metabolism in Cancer Biology and ImmunotherapyDingYuan Bai, Guo Cheng, Jing LingJie, QuanJun Yang, Zhou YuXuan대한면역학회 · Immune Network2025 · 제25권 제4호Targeting glutamine metabolism as a therapeutic strategy for cancer최연경, Byun Jun-Kyu, Jin Jonghwa, Park Keun-Gyu생화학분자생물학회 · Experimental and Molecular Medicine2023 · 제55권 Isocitrate dehydrogenase mutations: new opportunities for translational research금영삼, 최부영생화학분자생물학회 · BMB Reports2015 · 제48권 제5호Functional and pathologic association of aminoacyl-tRNA synthetases with cancerHan Jung Min, Kim Sunghoon, Sung Yulseung, Yoon Ina생화학분자생물학회 · Experimental and Molecular Medicine2022 · 제54권 Tumor bioenergetics: An emerging avenue for cancer metabolism targeted therapy기현정, 정재호생화학분자생물학회 · BMB Reports2014 · 제47권 제3호Metabolic reprogramming of the tumor microenvironment to enhance immunotherapy임선아생화학분자생물학회 · BMB Reports2024 · 제57권 제9호

이 간행물의 다른 논문 (12건)

Effect of Dose Escalation with Single Opioid, Fentanyl Matrix in Patients Not Controlling Cancer Pain: A Multicenter, Prospective, Observational Study in Korea박승우, 고성애, 류헌모, 남승현, 이경희, 김미정, 이규택pp. 263-269Trends in the Aggressiveness of End-of-Life Care for Advanced Stomach Cancer Patients홍지형, 노상영, 홍영선pp. 270-275Clinical Prognostic Factors for Locally Advanced Esophageal Squamous Carcinoma Treated after Definitive Chemoradiotherapy황준을, 정익주, 심현정, 김의진, 김미영, 최원영, 남택근, 배우균, 김승헌, 김민지, 나국주, 조상희, 김대은pp. 276-284Nomogram to Predict Treatment Outcome of Fluoropyrimidine/ Platinum-Based Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma박실비아, 맹치훈, 임영혁, 심영목, Antoine Adenis, Nicolas Penel, 정현애, 박세훈, 이지연, 안희경pp. 285-294Predictive Factors for Radiation Pneumonitis in Lung Cancer Treated with Helical Tomotherapy김영경, 홍성언, 공문규, 최진현pp. 295-302
원문 보기